Clinical Trial

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 30, 2024 (before its estimated March 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
In this study, the investigators provide a combined treatment of personalized tumor neoantigen-loaded dendritic cell (DC) vaccine, PD-1 Inhibitor, and radiotherapy to patients with advanced non-small cell lung cancer (NSCLC) progressed after second-line treatment. The investigators observe the objective response rate (ORR), disease control rate (DCR), adverse event (AE), serious adverse event (SAE), progression-free survival (PFS), and overall survival (OS) , aiming to evaluate the effectiveness and safety of the treatment.
Trial Details
NCT Number NCT06751849
Lead Sponsor The First Affiliated Hospital of Nanchang University
Conditions Advanced NSCLC
Enrollment 10 participants
Start Date 2024-03-11
Primary Completion 2026-03-10 (estimated)
Study Completion 2026-06-10 (estimated)
Updated on ClinicalTrials.gov 2024-12-30